Article
Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples.
AIDS (London, England) - 8 Sept 2000
Larder B A, Hertogs K, Bloor S, van den Eynde C H, DeCian W, Wang Y, Freimuth W W, Tarpley G
Abstract excerpt
OBJECTIVE: Although the use of HIV-1 protease inhibitors (PI) has substantially benefited HIV-1-infected individuals, new PI are urgently needed, as broad PI resistance and therapy failure is common. METHODS: The antiviral activity of tipranavir (TPV), a non-peptidic PI, was assessed in in vitro culture for 134 clinical isolates with a wide range of resistance to currently available peptidomimetic PI. The...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.